Conference Coverage

More evidence that modified Atkins diet lowers seizures in adults


 

FROM AES 2023

Cholesterol Concern

In Dr. Raj’s analysis, there was an increment in blood total cholesterol level after 3 months of MAD (standard mean difference, -0.82; 95% CI, -1.23 to -0.40; P = .0001).

Concern about elevated blood cholesterol affecting coronary artery disease risk may explain why doctors sometimes shy away from recommending the MAD to their adult patients. “Some may not want to take that risk; you don’t want patients to succumb to coronary artery disease,” said Dr. Raj.

She noted that 3 months “is a very short time period,” and studies looking at cholesterol levels at the end of at least 1 year are needed to determine whether levels return to normal.

“We’re seeing a lot of literature now that suggests dietary intake does not really have a link with cholesterol levels,” she said. If this can be proven, “then this is definitely a great therapy.”

The evidence of cardiovascular safety of the MAD includes a study of 37 patients who showed that although total cholesterol and low-density lipoprotein (LDL) cholesterol increased over the first 3 months of MAD treatment, these values normalized within 1 year of treatment, including in patients treated with MAD for more than 3 years.

Primary Diet Recommendation

This news organization asked one of the authors of that study, Mackenzie C. Cervenka, MD, professor of neurology and medical director of the Adult Epilepsy Diet Center, Johns Hopkins Hospital, Baltimore, Maryland, to comment on the new research.

She said that she was “thrilled” to see more evidence showing that this diet therapy can be as effective for adults as for children. “This is a really important message to get out there.”

At her adult epilepsy diet center, the MAD is the “primary” diet recommended for patients who are resistant to seizure medication, not tube fed, and are keen to try diet therapy, said Dr. Cervenka.

In her experience, the likelihood of having a 50% or greater seizure reduction is about 40% among medication-resistant patients, “so very similar to what they reported in that review,” she said.

However, she noted that she emphasizes to patients that “diet therapy is not meant to be monotherapy.”

Dr. Cervenka’s team is examining LDL cholesterol levels as well as LDL particle size in adults who have been on the MAD for 2 years. LDL particle size, she noted, is a better predictor of long-term cardiovascular health.

No conflicts of interest were reported.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

New European restrictions on topiramate in pregnancy
MDedge Neurology
Neurologic nuggets of wisdom for pediatric practice
MDedge Neurology
RNA therapeutics will ‘change everything’ in epilepsy
MDedge Neurology
Artificial intelligence presents opportunities, challenges in neurologic practice
MDedge Neurology
Yoga linked to seizure, anxiety reduction in epilepsy
MDedge Neurology
New consensus guide on rare drug hypersensitivity reaction
MDedge Neurology
FDA warns of potentially lethal reaction to seizure meds
MDedge Neurology
Sleep disorders linked to increased mortality risk in epilepsy
MDedge Neurology
Genetic testing warranted in epilepsy of unknown origin
MDedge Neurology
Poverty tied to poor cognition in patients with epilepsy
MDedge Neurology